QLS5132 + QL1706 + QL2107 + carboplatin + cisplatin + oxaliplatin

This combination therapy regimen is an investigational multi-agent protocol developed by Qilu Pharmaceutical for the treatment of advanced solid tumors, including ovarian, endometrial, gastric, and non-small cell lung cancers. The regimen centers on **QLS5132**, an antibody-drug conjugate (ADC) targeting **Claudin-6 (CLDN6)**, which is frequently upregulated in these tumor types. QLS5132 consists of a humanized anti-CLDN6 IgG1 antibody conjugated to a proprietary topoisomerase-1 inhibitor payload (QLS6916) via a hydrophilic cleavable linker. It is combined with **QL1706** (iparomlimab/tuvonivimab), a bifunctional antibody targeting PD-1 and CTLA-4, and **QL2107**, a monoclonal antibody targeting TIGIT. The regimen also incorporates platinum-based chemotherapy (carboplatin, cisplatin, or oxaliplatin) to enhance cytotoxic and immunogenic effects. This approach aims to leverage targeted ADC delivery, dual checkpoint blockade, and standard chemotherapy to overcome treatment resistance in CLDN6-positive malignancies.